Pfizer CEO highlights savings, leadership changes, and acquisition-driven growth amid significant revenue loss challenges ...

A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating symptoms. Research shows extended Paxlovid treatment could help restore ...

A report on the experiences of 13 patients found that the drug had no benefit for some and that some who benefited said the ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

Patients are reporting difficulties accessing the anti-COVID drug Paxlovid this winter, even as the coronavirus causing the infectious disease reaches levels not seen in months. Angela Carpio couldn’t ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer PFE.N COVID-19 treatment Paxlovid, Bristol Myers Squibb's BMY.N cancer cell therapies and vaccines ...

Pfizer Inc. convinced a federal judge in Massachusetts to cancel a patent Enanta Pharmaceuticals Inc. alleges its blockbuster Covid-19 antiviral Paxlovid infringes. Enanta’s changes to the patent, ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that ...

Enanta Pharmaceuticals (ENTA) announced Tuesday it would appeal a recent U.S. federal court ruling that favored Pfizer (NYSE:PFE) in a patent dispute over the pharma giant’s COVID-19 pill, Paxlovid.

The Tuschl lab has pioneered a novel class of antivirals targeting viral methyltransferases, enzymes essential to RNA viruses like SARS-CoV-2, Ebola, and dengue, paving the way for more effective ...

Online GLP-1RA products have become more prevalent amid popularity of Novo Nordisk’s and Eli Lilly’s approved treatments. Image credit: Shutterstock/ zimmytws. The US Food and Drug Administration (FDA ...

After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.